Sun, Dec 28, 2014, 11:56 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

OncoSec Medical Incorporated Message Board

  • jim.beemer@rocketmail.com jim.beemer Sep 6, 2013 10:54 AM Flag

    GSK Data Is Significant

    GSK study did not meet one of its key endpoints, and while they will press forward, the likelihood of FDA approval has now diminished.

    ONCS rallied double digits in response, as ONCS continues to trend higher, making the competitive landscape for ONCS more favorable. Now, there are three serious melanoma contenders: ONCS, NLNK, and AMGN.

    Thus, ONCS also becomes a more attractive acquisition target following its data in the next few months. This is a company that could be transformed if interim data repeats itself, going from $30m to $300m in a matter of weeks. The outlook for ONCS becomes more favorable by the day

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ONCS
0.47+0.02(+3.87%)Dec 26 3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.